HABS‑HD leadership and coordination for Alzheimer’s biomarker research
Official title: HABS-HD - Core A - Admin Core
Funded at University of North Texas Hlth Sci Ctr · NIH-11173808 · Data updated 2026-11-12
This team runs and coordinates a multi-part program that studies Alzheimer’s biomarkers in adults from diverse backgrounds to help improve future care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Texas Hlth Sci Ctr NIH-funded |
| Lab location | 1 site (Fort Worth, United States) |
| Project start | September 30, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,008,988 |
| NIH project number | 5U19AG078109-04 |
| Project ID | NIH-11173808 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (21+) including people with Alzheimer’s disease or related dementias and older adults from diverse racial and ethnic backgrounds who can attend research visits and share health information and samples.
✕Less likely to help
People without interest in research participation, those unable to travel to participating sites, or those who cannot or will not share medical data or samples are unlikely to directly benefit from this administrative core.
What this research studies
From a patient view, this core organizes and manages the HABS‑HD program that studies amyloid, tau, and neurodegeneration biomarkers across diverse adult populations. It brings together the projects, lab cores, committees, and investigators and makes sure timelines, data sharing, and quality standards are met. The core runs communication, annual meetings, and decision-making so the research activities (clinical visits, imaging, and specimen collection) stay coordinated. By keeping the program working smoothly, it helps produce reliable results that can be used to guide treatments and trial design.
Why it matters
Potential benefit: If successful, better-coordinated research could speed understanding of Alzheimer biomarkers in diverse groups and help make treatments and trials more equitable.
How similar studies have gone: Large biomarker efforts like ADNI have improved understanding of amyloid, tau, and neurodegeneration, but HABS‑HD is one of the comparatively few programs focused specifically on diverse populations.
Where this research is happening
-
University of North Texas Hlth Sci Ctr
Fort Worth, United States Active
Researchers
- Principal investigator: O'bryant, Sid E — University of North Texas Hlth Sci Ctr
- Study coordinator: O'bryant, Sid E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.